Blueshift Asset Management, LLC Zentalis Pharmaceuticals, Inc. Transaction History

Blueshift Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$41.58 - $80.89 $113,180 - $220,182	-2,722 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$66.92 - $84.79 $126,411 - $160,168	-1,889 Reduced 40.97%	2,722 $229,000
Q3 2021 Nov 12, 2021	BUY	$46.83 - $73.5 $215,933 - $338,908	4,611 New	4,611 $307,000
Q2 2021 Aug 13, 2021	SELL	$37.41 - $62.25 $182,785 - $304,153	-4,886 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$35.69 - $52.72 $57,889 - $85,511	-1,622 Reduced 24.92%	4,886 $212,000
Q4 2020 Feb 12, 2021	BUY	$31.71 - $57.97 $206,368 - $377,268	6,508 New	6,508 $338,000

143

68M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $128M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Blueshift Asset Management, LLC with notifications on news.